SCHEMBL6168641

SCHEMBL6168641

O=C(c1ccccc1)c1cc2c(Cl)cccc2[nH]1

nearest known ligand 0.60

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
FLT3 P36888 4/20 0.60
HTR6 P50406 1/20 0.56
MEN1 O00255 3/20 0.56
KMT2A Q03164 3/20 0.56
NPC1 O15118 1/20 0.56
RAB9A P51151 1/20 0.56
HRH4 Q9H3N8 1/20 0.52
DAO P14920 1/20 0.50
RHEB Q15382 1/20 0.49
ALOX15 P16050 2/20 0.48
CYP1A2 P05177 2/20 0.46
CYP3A4 P08684 1/20 0.46
CYP2C9 P11712 1/20 0.46
TSHR P16473 1/20 0.46
HDAC6 Q9UBN7 1/20 0.46
MAOB P27338 1/20 0.45
ADORA2A P29274 1/20 0.45
ADORA2B P29275 1/20 0.45
ADORA1 P30542 1/20 0.45
GRIN1 Q05586 2/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL970309 0.83 RHEB (0.62) FLT3MEN1KMT2AHRH4DAO
SCHEMBL29414287 0.83 RHEB (0.62) FLT3MEN1KMT2AHRH4DAO
SCHEMBL6168680 0.83 MEN1 (0.58) FLT3HTR6MEN1KMT2ANPC1
SCHEMBL6168465 0.83 GRIN1 (0.67) HTR6MEN1KMT2ANPC1RAB9A
SCHEMBL24020360 0.80 FLT3 (0.58) FLT3MEN1KMT2AHRH4DAO
SCHEMBL30310376 0.80 FLT3 (0.58) FLT3MEN1KMT2AHRH4DAO
SCHEMBL20505087 0.79 FLT3 (0.57) FLT3MEN1KMT2AHRH4DAO
SCHEMBL21200622 0.79 FLT3 (0.57) FLT3MEN1KMT2AHRH4DAO
SCHEMBL24112430 0.79 HRH4 (0.59) FLT3HRH4DAORHEBGRIN1
SCHEMBL29867215 0.79 FLT3 (0.57) FLT3MEN1KMT2AHRH4DAO

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1045833-B1 2,3-SUBSTITUTED INDOLE COMPOUNDS AS COX-2 INHIBITORS PFIZER (US) 2005-11-02 EP disclosed
US-6608070-B1 Useful for treatment of medical condition in which prostaglandins are implicated as pathogens NAKAO KAZUNARI (JP) 2003-08-19 US disclosed
CN-1284064-A 2,3-substituted indole compounds as cox-2 inhibitors PFIZER PHARMA (US) 2001-02-14 CN disclosed
EP-1045833-A1 2,3-SUBSTITUTED INDOLE COMPOUNDS AS COX-2 INHIBITORS PFIZER INC. (US) 2000-10-25 EP disclosed
WO-1999035130-A1 2,3-SUBSTITUTED INDOLE COMPOUNDS AS COX-2 INHIBITORS PFIZER PHARMACEUTICALS INC. (JP) 1999-07-15 WO disclosed